• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

Healthcare Holds Firm

The entire sector did well withstanding Tuesday's decline, but here are a few standouts.
By KATE STALTER Sep 27, 2012 | 09:15 AM EDT
Stocks quotes in this article: UNH, GILD, ALXN

The S&P 500 healthcare sector suffered minimal damage in Tuesday's broad-market selloff. The sector retreated Wednesday with the market -- but, as of Wednesday's close, the group is down only fractionally for the past week. Year to date, big-cap healthcare is down 0.5%, outperforming financials, consumer discretionary, technology and energy.

Naturally, attention has been focused on UnitedHealth Group (UNH), which joined the Dow industrials this week. As index-fund managers shuffled shares last week to mirror the shift, UnitedHealth rose 3.6% in heavier-than-average turnover. The stock is outpacing its index this week, having edged down 0.7% as of Wednesday's close. The Dow, meanwhile, has slumped 1.2% so far this week.

Thus far in 2012, UnitedHealth has advanced 10.1%, closing Wednesday at $55.78. The company confirmed plans to report its third quarter on Oct. 16 before market open.

Yet, if we glance at other S&P healthcare names, we see several names that are outgunning UnitedHealth on a year-to-date basis.

Pharmaceuticals and biotechs, in particular, have been among sector standouts. Gilead Sciences (GILD) has been on a tear lately, and is working on its fourth consecutive month of gains. The stock has advanced 61.4% in 2012, ending Wednesday's session at $66.06.

Even before it vaulted 9.3% last week, the stock had been rising on a few developments that had spurred optimism. Namely, Deutsche Bank and J.P. Morgan raised price targets on the stock, citing potential for HIV drug Stribild, which got the nod from regulators last month.

In addition, the company presented at UBS Global Life Sciences Conference last week. Such investment-banking conferences often result in boost for a stock as analyst get information about the firm's upcoming initiatives. Further, Jim Cramer mentioned that conference on air last week, noting that he saw further upside potential in Gilead, among other biotech names.

Gilead's technicals appear healthy, but the stock is a bit extended at the moment. Shares closed Wednesday slightly beneath their five-day exponential average, and could use a little time to consolidate all the recent gains before they're buyable again.

A large-cap growth name I've written about previously -- and a S&P 500 component -- is Alexion Pharmaceuticals (ALXN). The company makes treatments for autoimmune diseases, cancer and other ailments.

Alexion is up more than 56% year to date, having closed Wednesday at $111.96. This is one of those fairly unusual stocks that attracts investors seeking a large-cap, benchmark-index component, as well as those seeking a fast grower. It meets many of the classic fundamental and technical metrics that momentum investors seek: Earnings have risen at rates of 45% or more in every quarter of the past two years. Revenue rose 41% or more every quarter.

Looking ahead, analysts are eyeing an earnings increase of 37% this year, and 39% in 2013.

The stock has been trending along its 10-week moving average since a brief dip below that line in May. It rallied to an all-time high of $116.43 Tuesday, bucking the general market's downside reversal. It succumbed to the downdraft on Wednesday, however, closing 0.8% below its five-day line.

As with UnitedHealth and Gilead, Alexion is extended from a buy point at the moment. A consolidation of several weeks could wipe away some of the froth, and present a new technical entry point.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stalter had no positions in the stocks mentioned.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

There Are Market Bright Spots, but I View the July Rally as a Head Fake

Bret Jensen
Aug 3, 2022 10:30 AM EDT

It's hard to see stock valuations rising when inflation remains high and the economy appears headed for a recession if it isn't in one already.

A Recession Appears Inevitable, but There Are Still Places to Invest

Bret Jensen
Jul 27, 2022 10:30 AM EDT

A few homebuilders and healthcare stocks seem likely to hold up better than most of the market in a recession.

Change Healthcare Continues to Knock on a Breakout Level

Bruce Kamich
Jul 25, 2022 11:25 AM EDT

The CHNG chart is at an interesting juncture.

The Healing Process Begins for Cano Health

Bruce Kamich
Jul 21, 2022 1:30 PM EDT

Here's how to approach CANO as the shares have made a bottom formation.

With HCA Healthcare, I'm Getting Healthy Indications

Bruce Kamich
Jul 21, 2022 9:20 AM EDT

The healthcare provider is set to report earnings Friday.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:23 PM EDT STEPHEN GUILFOYLE

    We're Cleaning Out This Retailer From the Bullpen

    Check out the latest moves in TheStreet's Stocks U...
  • 10:24 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    To Improve Your Trading and Investing, Spend More ...
  • 08:44 AM EDT PETER TCHIR

    CPI Beats Expectations, But Maybe Not the 'Whisper'?

    Slightly better-than-expected inflation across the...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login